Kidney cancer management 3.0: can artificial intelligence make us better?
Matthew Lee, Shuanzeng Wei, Jordan Anaokar, Robert G. Uzzo, Alexander Kutikov
Abstract
PURPOSE OF REVIEW: Artificial intelligence holds tremendous potential for disrupting clinical medicine. Here we review the current role of artificial intelligence in the kidney cancer space. RECENT FINDINGS: Machine learning and deep learning algorithms have been developed using information extracted from radiomic, histopathologic, and genomic datasets of patients with renal masses. SUMMARY: Although artificial intelligence applications in medicine are still in their infancy, they already hold immediate promise to improve accuracy of renal mass characterization, grade, and prognostication. As algorithms become more robust and generalizable, artificial intelligence is poised to significantly disrupt kidney cancer care.